To de®ne genes that are essential to the initiation and progression of breast cancer we utilized subtractive hybridization and dierential display cloning techniques and isolated over 950 cDNAs from breast cell-lines derived from matched normal and tumor tissue. Of these, 102 cDNAs were characterized by DNA sequencing and Northern blot analysis. GenBank searches showed that one of these genes, T1A12 is identical to mac25, an insulin-like growth factor-binding protein related gene. Antibodies generated against the C-terminal region of the T1A12/mac25 protein were used to investigate its expression in 60 primary breast tissues. Sections of 12 benign, 16 ductal carcinoma in situ and 32 in®ltrating ductal carcinoma specimens were examined. Strong immunoperoxidase staining was observed in luminal epithelial cells of normal lobules and ducts, in apocrine cells of cysts and ®broadenomas. Moderate to weak protein expression was found in hyperplastic and DCIS cells, but no speci®c staining was detected in invasive carcinoma cells. FISH mapping using a PAC clone localized the T1A12/mac25 gene to 4q12-13. Microsatellite length polymorphism was studied using markers for 4q in paired normal and tumor breast tissues. Thirtythree per cent (10/30) of the samples were found to be polymorphic with D4S189 and D4S231 microsatellite markers and LOH was detected in 50% (5/10) of these informative samples. Our data indicate that T1A12/ mac25 expression is abrogated during breast cancer progression concomitant with loss of heterozygosity on chromosome 4q. T1A12/mac25 may therefore have a tumor suppressor-like function and its expression could indicate a disease with a more favorable status, having a better prognosis.
Introduction
Malignancy at the molecular level is partly due to genetic mutations and deletions that result in the alteration of expression and function of various cellular genes. Progressive and cumulative changes in cellular DNA result in mutational activation of growth proliferative genes (e.g. protooncogenes) or inactivation of growth inhibitory genes (e.g. tumor suppressor genes) (Tripathy and Benz, 1992; Patterson, 1992) . Molecular changes in genes such as c-erbB2, c-myc and p53 have been associated with breast cancer progression. Although substantial information exists supporting a role for the BRCA1 and BRCA2 genes in the familial or hereditary form of breast cancer, there has been no evidence as to their role in sporadic breast cancers (Futreal et al., 1994; Wooster et al., 1995) .
Genetic alterations, such as chromosomal losses at various regions have been implicated in the genesis of dierent types of primary tumors (Tarmin et al., 1994; Radford et al., 1995) . Loss of heterozygosity (LOH) at several chromosomal loci has been demonstrated in breast tumors at a relatively high incidence in patients with a poorer prognosis (Winqvist et al., 1993) . Thus screening for LOH in primary breast tumors may be of use in identifying patients with higher risk for developing aggressive disease with metastatic outcome. Moreover, to precisely de®ne genes that are essential to the initiation and progression of breast cancer it is necessary to isolate and characterize activated and inactivated genes during various stages of cancer. This strategy will provide the needed genetic ®ngerprints of expressed genes which will enable the assessment of the tumorigenic potential of aected cells.
In order to identify and isolate genes that may be associated with the progression of breast carcinomas through various stages of neoplastic development, we employed subtractive-hybridization and dierential display cloning using RNA from matched tumor and normal breast cell-lines. We obtained more than 950 breast cancer associated genes (Burger et al., 1996a; Burger et al., in press ). GenBank comparisons showed that thirty clones had unique sequences. One of these genes, T1A12, was later in fact found to be identical with the mac25 gene (Murphy et al., 1993) . The predicted amino acid sequence of T1A12/mac25 contains a signal peptide and a cysteine rich IGF-I binding motif similar to those of insulin-like growth factor binding proteins (Figure 1) (Murphy et al., 1993; Swisshelm et al., 1995) .
We have shown that T1A12/mac25 protein in conditioned medium of Hs578T/HTB126 cells binds IGF-I, a result consistent with the recent demonstra-tion by anity cross-linking, that recombinant mac25 also associates with IGF-I (Burger et al., 1996b; Oh, 1996) . Collectively, these data suggest that T1A12/ mac25 may modulate the mitogenic eects of IGF-I in normal and breast cancer cells. To further examine the function of T1A12/mac25 in breast cancer progression, we generated anti-T1A12/mac25 speci®c antibodies, and used immunohistochemical staining to correlate T1A12/mac25 expression with various stages of breast cancer development. We found that T1A12/mac25 protein expression decreases with disease progression in breast carcinomas. In addition T1A12/mac25 mRNA was found to be primarily expressed in various normal tissues, in cell-lines derived from normal human mammary epithelial cells, and was rarely expressed in breast cancer cell-lines. By FISH we mapped the T1A12/mac25 gene to chromosomal location 4q12 ± 13. Microsatellite markers spanning this region were used to examine 4q12 ± 13 allelic loss in primary tumor samples. Loss of heterozygosity was observed in 50% of the informative samples using microsatellite markers D4S189 (4p15 ± 4q23) and D4S231 (4q11 ± 31). Our data indicate that T1A12/ mac25 expression decreases with disease progression, concomitant with loss of heterozygosity on chromosome 4q.
Results

Isolation and characterization of the T1A12/mac25 gene
Single stranded cDNA libraries enriched for breast cancer or normal cDNAs were constructed using mRNAs from tumor (Hs578T/HTB126) and normal (Hs578Bst/HTB125) cell-lines which are derived from the same patient. After subtractive and dierential display cloning 950 clones were isolated. One of these clones, named T1A12, was found to be dierentially expressed in cancer and normal breast cell-lines. Initial database searches using NCBI-BLAST analysis found no matching sequence, however, later searches showed that T1A12 is identical to mac25, which has been recently termed insulin-like growth factor binding protein related gene 7 (IGFBP-7) (Murphy et al., 1993; Swisshelm et al., 1995; Sato et al., 1995; Kato et al., 1996) . Comparison of amino acid sequences between T1A12/mac25, IGFBP-1, and follistatin is shown in Figure 1 . Overall T1A12/mac25 has approximatley 25% homology with IGFBP-1 to IGFBP-6, having maximal homology to the IGFBP-1 (Figure 1a) . At the N-terminal region there are eight contiguous amino acids identical to those of IGFBP-1 containing four conserved cysteines which are essential for IGF-I binding since mutation in these residues results in the loss of IGF-I binding activity ( Figure 1a ) (Ooi, 1990) . T1A12/mac25 also has signi®cant homology to follistatin, an activin-binding protein which has been shown to be associated with cell-growth arrest (Kato et al., 1996) .
T1A12/mac25 is expressed in normal breast cell lines and in primary tissues
To determine the expression pattern of T1A12/mac25 RNA in normal tissues and breast cell-lines, we performed Northern blot analysis. In a normal tissue RNA blot (Clontech) T1A12/mac25 was found to be expressed in the spleen, prostate, testes, ovaries, small intestine, and colon. T1A12/mac25 was expressed at very low levels in the thymus, and not at all in PBLs (Figure 2a ). T1A12/mac25 RNA was expressed in normal human mammary epithelial cells (Figure 2b ). With the exception of the Hs578T/HTB126 and MDA-MB-231 cell-lines, no T1A12/mac25 RNA was observed in breast cancer cell-lines (MCF-7, T47D, ZR75-1, MDA-MB-453, BT20) (Figure 2b ).
Dierential expression of the T1A12/mac25 protein product in breast cancer cell lines Anity puri®ed anti-T1A12/mac25 antibody was used to immunohistochemically detect T1A12/mac25 protein in various normal and cancerous breast cell-lines (Figure 3) . In order to avoid cross-reactive staining with other IGFBP-related proteins, we developed antibodies against a T1A12/mac25 speci®c region that has no homology to other known IGFBPs (Figure 1b) . staining in these cell-lines were found to be identical to the relative levels of T1A12/mac25 RNA described above.
Expression of T1A12/mac25 decreases with breast cancer progression
To evaluate whether T1A12/mac25 is dierentially expressed in primary breast tissues and to correlate its expression with breast cancer progression, 60 primary tissue samples were analysed. Paran embedded sections of 12 benign, 16 ductal carcinoma in situ, and 32 in®ltrating ductal carcinomas were examined using anti-T1A12/mac25 antibody with a biotin/streptavidin/peroxidase/diaminobenzidine (DAB) detection system ( Figure 4 ). Strong T1A12/ mac25 protein expression was found in all 12 benign tissue samples and strong staining was observed in luminal epithelial cells of normal lobules and ducts, in the epithelial layer of atrophic acini/®brocystic disease, in benign proliferation of ducts consistent with ®broadenoma, in apocrine cells of cysts, in the endothelial cell layer of blood vessels and in the trophoblast layer of chorionic villi of placental tissue ( Figure 4 ). Weaker staining was seen in all 16 DCIS sections. A representative specimen illustrating prominent basal membrane cell staining with strongly stained epithelial cells in benign atrophic acini adjacent to weakly stained DCIS cell is shown in Figure 5 . Signi®cantly, all 32 IDC specimens lacked detectable T1A12/mac25 protein expression (Figure 4 ).
Chromosomal localization of T1A12/mac25
To investigate whether T1A12/mac25 is associated with allelic loss in breast tumors, we determined its chromosomal location. PAC clones were isolated to obtain large genomic DNA fragments for use as probes in FISH mapping. T1A12/mac25 was localized to the chromosome subregion 4q12 ± 13 ( Figure 6 ).
Loss of 4q heterozygosity in paired normal and tumor breast tissues
A loss of T1A12/mac25 expression during disease progression was observed by immunohistochemical evaluation of normal, benign, and malignant breast tissues, which suggested to us that it may have a tumor growth suppressing function. To determine if this loss occurs at the DNA level, a microsatellite marker based method was used to determine allelic loss of the T1A12/mac25 locus in paired normal and tumor breast tissues. Inactivation of tumor suppressor genes can occur by germline mutation in one allele, with a subsequent inactivation by mutation or deletion of the second allele in tumor cells (Knudson, 1971) . Thirty matched normal and tumor DNA specimens from microdissected tissues were tested for microsatellite length polymorphisms with two markers of the long arm region of chromosome 4. Ten of thirty samples were found to be polymorphic for both D4S189 (4p15 ± 4q23) and D4S231 (4q11 ± 4q31) microsatellite loci. Loss of heterozygosity of these microsatellite loci was detected in 50% (5/10) of polymorphic samples using an automated DNA sequencer and¯uorescently labeled primers. Allelic loss was determined by 
Discussion
In order to identify and isolate genes whose expression is associated with breast carcinomas in various stages of neoplastic development, we employed subtractivehybridization and dierential display-PCR cloning techniques (Liang and Pardee, 1992; Schweinfesst et al., 1990; Salesiotis et al., 1995) . Over 950 clones were obtained and 102 cDNAs were sequenced and analysed by computer searching and 30 were found to be unique. Data mining of the ®rst group of 102 clones revealed cDNAs encoding known and unknown genes for growth factors and their receptors, protein kinases, transcription factors, and other genes involved in signal transduction in normal and tumor development. Northern blot analysis of novel clones revealed dierential expression patterns in breast cell-lines, primary breast tumors, and normal tissues. Expression analysis of these genes is being done more eciently and in parallel to produce hybridization signatures for particular stages of breast cancer.
One of these genes, T1A12/mac25, was found to be a novel member of the insulin-like growth factor binding protein family (Murphy et al., 1993; Swisshelm et al., 1995; Oh et al., 1996; Kato et al., 1996) . T1A12/mac25 is most closely related to IGFBP-1, as shown by its protein sequence (Figure 1) (Murphy et al., 1993; Swisshelm et al., 1995) . Previously, we have found speci®c association of IGF-I with a 31 kd protein, the expected size of the T1A12/mac25 gene product, that is known to be present in conditioned medium obtained from the breast cancer cell-line Hs578T/HTB126, from which T1A12/mac25 was cloned (Burger et al., 1996) . Recently, others using an anity cross-linking assay with recombinant mac25 protein showed a similar association of T1A12/mac25 to IGF-I (Oh et al., 1996b) . The binding of T1A12/ mac25 with IGF-I suggests that it may be able to modulate the mitogenic eects of IGF-I in normal and breast cancer cells. There are six known species of IGFBPs which regulate the interaction between IGF-I and -II and their receptors (Clemmons, 1992) .
IGF-I and -II play important roles in normal growth and development and have been implicated as growth regulators and potent mitogens, particularly in breast cancer. In fact overexpression or inappropriate expression of IGF-I and IGF-II have been characterized as unrecognized oncogenes (Westley and May, 1995; Bates et al., 1995) . Thus, their binding proteins (Yee et al., 1994; Pekonen et al., 1992) and the use of exogenous IGFBPs as strategy to suppress breast cancer cell growth has been suggested (McGuire et al., 1992) . Recently, the insulin-like growth factor system established in transformed/immortalized benign prostate epithelial cells and sublines demonstrated an increased proliferation concomitant with increased IGF-I expression (Plymate et al., 1996) . As cells became progressively more tumorigenic there was a corresponding decrease in IGFBPs 2 ± 6 in the medium. Unfortunately evidence for a tumorigenic role for overexpressed IGF factors is only just accumulating (Westley and May, 1995) . Nonetheless evidence for involvement of IGF signal transduction pathways in malignancy is becoming stronger Baserga, 1997) . It is important to note that IGFs have been implicated as mediators in the proliferative eects of steroids in hormone responsive breast cancers and therefore therapeutic strategies that can reduce circulating IGF are being investigated (Pollak et al., 1990) .
To examine a possible tumor suppressor role for T1A12/mac25, we used immunohistochemistry and PCR-LOH methods to determine at which stages of tumor development T1A12/mac25 is inactivated. We found that the T1A12/mac25 gene product is strongly expressed in normal and benign breast tissues, at low or undetectable levels in non-invasive breast cancers (DCIS), and is virtually lost in all the invasive cancers investigated (Figures 4 and 5) . Within the DCIS cases examined, there was variable T1A12/ mac25 protein expression, which could arise as a result of diering DCIS sub-types or stages and thus might become a useful tool to distinguish various degrees of malignant progression within non-invasive breast cancers.
To determine whether loss of T1A12/mac25 gene expression occurs concomitantly with allelic loss, we performed LOH analysis with microsatellite markers. DNA from paired normal and tumor breast tissues revealed LOH in 50% of informative samples (5/10). Our data together with transfection-transformation experiments provides evidence that the T1A12/mac25 gene, may be able to eect tumor suppressor activities by speci®cally modulating interacting mitogenic-growth factors (Kato et al., 1996) . The murine mac25 gene has been found to have growth-suppressing activity in a p53-de®cient osteosarcoma cell-line (Sato et al., 1995; Kato et al., 1996) . Moreover transcription of mac25 was found to be down-regulated in mammary carcinoma cells and up-regulated in senescent normal mammary epithelial cells, implying a tumor suppressor role for this gene (Swisshelm et al., 1995) .
Considering an alternative functional role, it appears that T1A12/mac25 protein expression is concentrated in the cytoplasm of luminal epithelial cells, in ducts and acini of normal (from breast reductions) and in benign primary breast tissues as well as other luminal, normal human cellular structures, such as trophoblastic cell layers in placental tissue and cultured and/or endothelial cells of blood vessels. This expression pattern may indicate a vital role for T1A12/mac25 in the maintenance of normal breast and tissue architecture in general. Indeed, Akaogi et al. described the isolation of a 33 kd protein, with a high degree of similarity to the putative T1A12/mac25 protein and named it tumorderived adhesion factor (TAF) (Akaogi et al., 1996) . They found that it binds to type IV collagen, thus stabilizing the three-dimensional architecture of capillary tubes (Akaogi et al., 1996) . Although these investigators found TAF in blood vessels, which vascularize esophageal, brain, glioblastoma and squamous cell carcinomas, they could not detect it in the tumor cells. Since TAF is related to the T1A12/ mac25/IGFBP-7 protein, this suggests that this particular gene is important not only for breast cells, but also for the malignant development of many other types of cancers.
Keratins and type IV collagen are known to be an important part of the luminal breast epithelial-cell architecture (Bocker et al., 1992) , T1A12/mac25/ IGFBP-7/TAF binding could then be a regulator of an important type of functional structural assembly; down-regulation or loss of T1A12/mac25 expression might then lead to a collapse/disappearance of normal breast ducts and acini and thus contribute to the atrophic acini and lobular cancerization by DCIS Figure 6 T1A12/mac25 is located at 4q12 ± 13. A PAC clone containing T1A12/mac25 genomic sequences was used in FISH mapping. Band assignments were determined by measuring fractional chromosome length and analysing the banding pattern generated by DAPI counterstained image progression of uncontrolled cell proliferation, differentiation and invasion processes characteristic of most advanced cancers.
In summary, our data indicate that T1A12/mac25/ IGFBP-7 expression is abrogated during disease progression concomitant with allelic loss on chromosome 4q noted in breast cancer. These observations suggest that this gene may have a tumor suppressor or associated function. T1A12/mac25 expression may be a useful indicator of a more favorable proliferation status and be useful therefore in clinical prognosis.
The modulation of its expression could be used to suppress tumor cell growth.
Materials and methods
Cell lines
Human normal breast and breast cancer cell-lines were obtained from the ATCC (Rockville, MD). BT-474 cells were a gift from Prof WJ Gullick, Hammersmith Hospital, London. The BTS-30 primary breast line was established from adjacent normal tissue of a breast cancer specimen (Hambly, 1994) .
Tissue samples
Paran-embedded tissues were obtained from the breast cancer unit at Bradford Royal In®rmary (BRI). Tissues were promptly ®xed in 12% neutral buered formaldehyde and processed routinely in paran wax. Fresh tissues for RNA isolation were provided by Women's College Hospital, Toronto, snap-frozen in liquid nitrogen directly after removal and stored at 7708C. Clinical specimens and patient information were used in accordance with ethics committee approval.
RNA extraction and Northern blot analysis
Total RNA was extracted from cell pellets or tissue samples using the RNAzol B method (Tel-Test Inc, Friendswood, TX). Poly-A RNA was isolated with oligodT columns (Pharmacia) following the manufacturer's instructions. About 20 mg RNA/sample from cell-lines, tumor, or normal tissues was separated on 1.2% agarose gels, transferred onto nitrocellulose membranes and probed with 32 P-labeled T1A12/mac25 cDNA.
Sequencing and data base analysis 
T1A12/mac25 antibodies
Antibodies were raised in rabbits against a synthetic peptide sequence, LSKEDAGEYE, derived from the T1A12/mac25 C-terminal region and conjugated to keyhole limpet hemocyanin (KLH). Rabbit IgG polyclonal antibodies were puri®ed on a peptide anity column.
Immunohistochemistry
The HistoStain TM SP kit (rabbit, Zymed, San Francisco, CA) was used for immunohistochemical analysis of T1A12/ mac25 protein in paran-embedded breast cancer cell-lines and breast tissues. Immunoperoxidase staining was as described (Soubeyran et al., 1995) with the modi®cation that removal of endogenous peroxidase was followed by incubation in 0.1% trypsin (pH 7.8). T1A12/mac25 antibody (dil. 1 : 25, 40 mg/ml) was added for 2 h at room temperature, negative control sections were incubated with rat immunoglobulins (DAKO, Denmark) or preimmune serum. The Elston-modi®ed Bloom and Richardson method was used for histological grading of breast tumors (Elston and Ellis, 1991) .
FISH mapping
T1A12/mac25 was mapped using a corresponding PAC. The probe was labeled with biotin-14-UTP by nick translation. The position of hybridization was determined by the¯uorescence emission generated by the¯uorochrome FITC on DAPI banded metaphase preparations.
DNA isolation from microdissected malignant breast tissues DNA was extracted from frozen section trimmings adjacent to a hematoxylin/eosin (H and E) stained section assessed for tumor content. The tumor content in the samples was estimated to be 50 ± 100%. Matched control sections were con®rmed as tumor-free normal tissue by H and E staining before extraction. The sections were incubated for 24 h with Proteinase K (2 mg/ml, Sigma, Poole, Dorset, UK) and 1% SDS at 378C (Bell et al., 1991) . This step was followed by extraction twice with phenol/chloroform/isoamyl alcohol (25 : 24 : 1) and precipitated with ethanol. Resuspended DNA was quantitated on a mini¯uorometer (Hoefer Scienti®c Instruments San Francisco, CA, USA).
LOH with microsatellite markers on chromosome 4
Human microsatellite markers on chromosome 4 were purchased from Research Genetics, Inc. (Huntsville, AL, USA). MapPairs TM used were D4S189 (4p15 ± q23) and D4S231 (4q11 ± q31). The forward primer of each pair was labeled with the¯uorescent dye FAM amidite to enable detection by an automated DNA sequence analyser. Genomic DNA (25 ± 50 ng) from microdissected matched tumor and normal breast tissues was ampli®ed by PCR in a reaction volume of 25 ml containing 12.5 pmoles of each primer, 0.95 units AmpliTaq Gold (Perkin Elmer, Foster City, CA), 16GeneAmp PCR buer (Perkin Elmer), 1.5 mM MgCl 2 and 50 mM dNTP mix. AmpliTaq Gold Taq DNA polymerase was activated at 958C for 11 min followed by 35 cycles at 948C 30 s, 558C 60 s and 728C 45 s and a ®nal incubation at 728C for 5 min. PCR products were then analysed on 6% polyacrylamide denaturing gels in 16TBE buer with an automated uorescent DNA sequencer (Cawkwell et al., 1993 ) (Model 393A, Applied Biosystems, Foster City, CA, USA). At least two independent¯uorescent detection assays were performed for each marker. In addition, autoradiographic detection was used, wherein [a- 32 P]dCTP was added to the reaction mix (2 mCi/sample) and thē uorescent forward primer was replaced with the unlabeled primer. PCR products were run on 6% denaturing polyacrylamide gels for 3 h. Dried gels were exposed to X-ray ®lms for 24 h at 7708C.
